Financial PerformanceCurrent cash of $363.6mm is expected to fund operations into early-'27.
Partnerships And CollaborationsRGNX entered a partnership with Nippon Shinyaku to commercialize RGX-121 in the US and Asia in exchange for $110M upfront and $700M in potential milestones.
Regulatory ApprovalsRGX-121 has received Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA and advanced therapy medicinal products (ATMP) classification from the European Medicines Agency.